Home » NICOX, TOPIGEN SIGN DEAL ON RESPIRATORY DRUG
NICOX, TOPIGEN SIGN DEAL ON RESPIRATORY DRUG
French biotechnology company NicOx said on Thursday it had signed an agreement giving Canadian-based Topigen the North American rights to develop and market its experimental NCX 1020 treatment for inflamed lungs. Under the statement NicOx would receive a 2 million euro ($2.4 million) upfront payment and up to 52.9 million euros in milestones and commercial success fees in addition to a share in future revenues, it said in a statement.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May